OR Royalties (OR) Expected to Announce Quarterly Earnings on Wednesday

OR Royalties (NYSE:OR) is projected to post its Q4 2025 results before the market opens on Wednesday, February 18th. Analysts expect OR Royalties to post earnings of $0.31 per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 10:00 AM ET.

OR Royalties Stock Performance

OR Royalties stock opened at $42.72 on Tuesday. The stock has a market cap of $8.01 billion, a PE ratio of 54.08 and a beta of 0.76. The stock has a 50-day moving average of $39.42 and a two-hundred day moving average of $35.92. OR Royalties has a one year low of $17.55 and a one year high of $47.75.

Institutional Trading of OR Royalties

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN grew its position in shares of OR Royalties by 6.2% in the fourth quarter. Wells Fargo & Company MN now owns 5,901 shares of the basic materials company’s stock valued at $209,000 after purchasing an additional 346 shares in the last quarter. Merit Financial Group LLC acquired a new position in OR Royalties during the third quarter worth $215,000. Flow Traders U.S. LLC purchased a new stake in OR Royalties in the 3rd quarter valued at $217,000. Moors & Cabot Inc. acquired a new stake in shares of OR Royalties in the 3rd quarter worth $220,000. Finally, Envestnet Asset Management Inc. purchased a new position in shares of OR Royalties during the 3rd quarter worth $228,000. Institutional investors and hedge funds own 68.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on OR shares. Scotiabank increased their price objective on shares of OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a research report on Monday, January 26th. Jefferies Financial Group reiterated a “hold” rating and set a $38.00 price objective on shares of OR Royalties in a research note on Sunday, December 7th. Wall Street Zen raised OR Royalties from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Canadian Imperial Bank of Commerce reaffirmed an “outperform” rating on shares of OR Royalties in a research report on Wednesday, February 4th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of OR Royalties in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $38.25.

OR Royalties Company Profile

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.